Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Andrologia ; 48(7): 765-73, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26688565

RESUMEN

In this study, our objective was to evaluate the impact of testicular histopathology on the outcome of intracytoplasmic sperm injection (ICSI) cycles of patients with nonobstructive azoospermia and correlate with clinical and hormonal parameters. For this purpose, 271 patients with nonobstructive azospermia (NOA) who underwent testicular sperm extraction (TESE) for ICSI cycles were retrospectively evaluated for sperm retrieval, fertilisation, embryo cleavage, clinical pregnancy and live birth rates among different testicular histology groups. We also correlated hormonal and clinical factors with histological findings. Sperm retrieval and fertilisation rates (FR) were found to be significantly different among all testicular histological groups of NOA except for embryo cleavage, clinical pregnancy and live birth rates. Furthermore, serum follicle stimulating hormone (FSH) level was the most significant variable to predict sperm recovery on TESE. Separate analyses within each testicular histological group revealed that higher FSH was also associated with lower pregnancy rates in only maturation arrest group. In conclusion, testicular histology significantly influences sperm retrieval and FRs but not pregnancy and live birth rates in nonobstructive azoospermia. However, FSH is the best predictor of a successful TESE.


Asunto(s)
Azoospermia/terapia , Hormona Folículo Estimulante Humana/sangre , Resultado del Embarazo , Inyecciones de Esperma Intracitoplasmáticas , Recuperación de la Esperma , Testículo/patología , Adulto , Factores de Edad , Tasa de Natalidad , Femenino , Humanos , Masculino , Embarazo , Estudios Retrospectivos , Espermatozoides , Resultado del Tratamiento , Turquía
2.
Clin Exp Obstet Gynecol ; 43(5): 661-665, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-30074315

RESUMEN

In spite of the fact that migraines are one of the major problems seen by primary care providers, almost half of people with migraines do not obtain appropriate diagnosis or treatment. Migraine occurs in about 18% of women, and is often aggravated by hormonal shifts occurring around women's menses, during pregnancy, and during perimenopause. Quality of life with migraines is often greatly diminished, and many women miss work days with migraines. In women, the hormonal fluctuations seen during pregnancy and lactation can affect migraine frequency and magnitude. Understanding the evaluation of headache in pregnancy is important, especially given the increased risk of secondary headache conditions. Pregnancy and lactation can complicate treatment options for women with migraine because of the risk of certain medications to the fetus. This review includes details of the workup and then provides treatment options for migraine during pregnancy and lactation.


Asunto(s)
Trastornos Migrañosos/tratamiento farmacológico , Complicaciones del Embarazo/tratamiento farmacológico , Lactancia Materna , Femenino , Cefalea/tratamiento farmacológico , Cefalea/etiología , Humanos , Lactancia , Trastornos Migrañosos/epidemiología , Trastornos Migrañosos/etiología , Trastornos Migrañosos/psicología , Embarazo , Calidad de Vida
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...